Overriding Adaptive Resistance to Sorafenib Through Combination Therapy With Src Homology 2 Domain-Containing Phosphatase 2 Blockade in Hepatocellular Carcinoma.
Carmen Oi Ning LeungMan TongKatherine Po Sin ChungLena ZhouNoélia CheKwan Ho TangJin DingEunice Yuen Ting LauIrene Oi Lin NgStephianie MaTerence Kin-Wah LeePublished in: Hepatology (Baltimore, Md.) (2020)
SHP2 blockade by SHP099 in combination with sorafenib attenuated the adaptive resistance to sorafenib by impeding RTK-induced reactivation of the MEK/ERK and AKT signaling pathways. SHP099 in combination with sorafenib may be a safe therapeutic strategy against HCC.